MedPath

Effects of Provider Commitments to Choose Wisely

Not Applicable
Completed
Conditions
Guideline Adherence
Health Care Costs
Unnecessary Procedures
Health Services Misuse
Physician's Practice Patterns
Interventions
Behavioral: Commitment Invitation for Clinicians (Clinician Intervention)
Other: Health Education Materials to Patients (Patient Intervention)
Registration Number
NCT03411525
Lead Sponsor
University of Michigan
Brief Summary

Clinicians' decisions to order potentially unnecessary services -- such as those targeted in the Choosing Wisely® campaign -- are often affected by their high-pressure practice environments, which can make it hard to consistently avoid ordering low-value care. The field of behavioral economics offers a promising and highly scalable approach to decreasing use of low-value services: asking clinicians to commit to avoid ordering such services and providing them and their patients with resources to support adherence to this commitment. This project will evaluate the effects of such an intervention across 2 large health systems, Michigan Medicine and IHA, through a mixed-methods, stepped wedge cluster randomized trial. In each of the study clinics, clinicians will be invited to commit to following a set of targeted Choosing Wisely® recommendations. Clinicians who make such a commitment, and their patients, will receive access to key resources to support adherence to this commitment. To measure the effects of the intervention, automated clinical data and medical record data before and after the intervention will be examined. Surveys and semi-structured interviews of both clinicians and patients will also be conducted to determine the effects of the intervention on their decision-making and experiences.

Detailed Description

A mixed-methods stepped wedge cluster randomized trial will be conducted in 8 primary care clinics of IHA, a private multispecialty group practice, and Michigan Medicine, a large academic health system. The study will test whether pre-encounter clinician commitments combined with patient and provider supports decrease overtreatment of type 2 diabetes among patients 65 and older, use of benzodiazepines and sedative-hypnotics among patients age 65 and older who have insomnia or anxiety, and use of PSA tests to screen for prostate cancer among men 75 and older. These 3 recommendations were chosen because they are commonly performed in primary care practice, have Choosing Wisely® recommendations against these low-value services, and represent situations in which clinician decisions about ordering of services can be unduly swayed by interactions with patients.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
489
Inclusion Criteria
  • Clinician participants will be drawn from the pool of physicians, nurse practitioners, and physician assistants staffing the 8 primary care clinics.

  • Patients of all 8 study clinics must meet criteria for one of the three Choosing Wisely® recommendations to be eligible to participate:

    • 65 and older with type 2 diabetes
    • 65 and older with insomnia and/or anxiety
    • male, 75 and older with no history of prostate cancer.
Read More
Exclusion Criteria
  • Patients who have cognitive impairment and/or a serious psychiatric diagnosis will not be eligible to participate in the surveys or interviews.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Commitment invitation at time 1Commitment Invitation for Clinicians (Clinician Intervention)In the stepped wedge cluster randomized design, the first clinic will remain in the control period (no intervention) for 1 month, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 8 months.
Commitment invitation at time 2Health Education Materials to Patients (Patient Intervention)In the stepped wedge cluster randomized design, the second clinic will remain in the control period (no intervention) for 2 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 7 months.
Commitment invitation at time 3Commitment Invitation for Clinicians (Clinician Intervention)In the stepped wedge cluster randomized design, the third clinic will remain in the control period (no intervention) for 3 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 6 months.
Commitment invitation at time 4Health Education Materials to Patients (Patient Intervention)In the stepped wedge cluster randomized design, the fourth clinic will remain in the control period (no intervention) for 4 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 5 months.
Commitment invitation at time 1Health Education Materials to Patients (Patient Intervention)In the stepped wedge cluster randomized design, the first clinic will remain in the control period (no intervention) for 1 month, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 8 months.
Commitment invitation at time 2Commitment Invitation for Clinicians (Clinician Intervention)In the stepped wedge cluster randomized design, the second clinic will remain in the control period (no intervention) for 2 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 7 months.
Commitment invitation at time 3Health Education Materials to Patients (Patient Intervention)In the stepped wedge cluster randomized design, the third clinic will remain in the control period (no intervention) for 3 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 6 months.
Commitment invitation at time 4Commitment Invitation for Clinicians (Clinician Intervention)In the stepped wedge cluster randomized design, the fourth clinic will remain in the control period (no intervention) for 4 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 5 months.
Commitment invitation at time 5Commitment Invitation for Clinicians (Clinician Intervention)In the stepped wedge cluster randomized design, the fifth clinic will remain in the control period (no intervention) for 5 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 4 months.
Commitment invitation at time 5Health Education Materials to Patients (Patient Intervention)In the stepped wedge cluster randomized design, the fifth clinic will remain in the control period (no intervention) for 5 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 4 months.
Commitment invitation at time 6Commitment Invitation for Clinicians (Clinician Intervention)In the stepped wedge cluster randomized design, the sixth clinic will remain in the control period (no intervention) for 6 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 3 months.
Commitment invitation at time 8Health Education Materials to Patients (Patient Intervention)In the stepped wedge cluster randomized design, the eighth clinic will remain in the control period (no intervention) for 8 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 1 month.
Commitment invitation at time 6Health Education Materials to Patients (Patient Intervention)In the stepped wedge cluster randomized design, the sixth clinic will remain in the control period (no intervention) for 6 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 3 months.
Commitment invitation at time 7Commitment Invitation for Clinicians (Clinician Intervention)In the stepped wedge cluster randomized design, the seventh clinic will remain in the control period (no intervention) for 7 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 2 months.
Commitment invitation at time 7Health Education Materials to Patients (Patient Intervention)In the stepped wedge cluster randomized design, the seventh clinic will remain in the control period (no intervention) for 7 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 2 months.
Commitment invitation at time 8Commitment Invitation for Clinicians (Clinician Intervention)In the stepped wedge cluster randomized design, the eighth clinic will remain in the control period (no intervention) for 8 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 1 month.
Primary Outcome Measures
NameTimeMethod
Difference in the proportion of intervention and control period visits with an applicable low-value treatment or test as specified by each respective Choosing Wisely® recommendation10 months

The applicable low-value treatments or tests specified by the respective Choosing Wisely® recommendations are use of hypoglycemic medications for patients 65 years or older with diabetes and tight glycemic control, PSA testing among men 75 years or older with no history of prostate cancer, and use of benzodiazepine or sedative-hypnotic medications for patients with insomnia or anxiety who are 65 years or older.

Secondary Outcome Measures
NameTimeMethod
Frequency of patient-provider conversations about the applicable low-value treatments or testsWithin 1 week of primary care visit

Self-reported frequency of patient-provider conversations about the applicable low-value treatments or tests. The applicable low-value treatments or tests specified by the respective Choosing Wisely® recommendations are use of hypoglycemic medications for patients 65 years or older with diabetes and tight glycemic control, PSA testing among men 75 years or older with no history of prostate cancer, and use of benzodiazepine or sedative-hypnotic medications for patients with insomnia or anxiety who are 65 years or older.

Patient trust in primary care providerWithin 1 week of primary care visit

Self reported level of trust patient has in his or her primary care provider as measured by a 5-item scale.

Patient rating of providerWithin 1 week of primary care visit

Patient's self-reported rating of their primary care provider as measured on a 0 to 10 scale.

Composite difference in the proportion of intervention and control period visits with an applicable low-value treatment or test as specified by each respective Choosing Wisely® recommendation10 months

The study will combine data from all target recommendations (e.g., a composite outcome) where if one visit meets inclusion criteria for more than one target recommendation, they will be treated as independent visits.

Trial Locations

Locations (9)

IHA Family & Internal Medicine - West Arbor

🇺🇸

Ann Arbor, Michigan, United States

Michigan Medicine Briarwood Medical Group

🇺🇸

Ann Arbor, Michigan, United States

Michigan Medicine East Ann Arbor Health and Geriatrics Center

🇺🇸

Ann Arbor, Michigan, United States

Michigan Medicine Brighton Health Center

🇺🇸

Brighton, Michigan, United States

IHA Internal Medicine - Domino's Farms

🇺🇸

Ann Arbor, Michigan, United States

IHA Family & Internal Medicine - Cherry Hill

🇺🇸

Canton, Michigan, United States

University of Michigan Medical School

🇺🇸

Ann Arbor, Michigan, United States

Michigan Medicine Canton Health Center

🇺🇸

Canton, Michigan, United States

IHA Internal Medicine - Towsley

🇺🇸

Ypsilanti, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath